お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
市場調査レポート
商品コード
982372

医療関連感染症診断の市場調査レポート:製品とサービス別、疾患タイプ別、エンドユーザー別(2025年までの世界予測-COVID-19の累積的影響)

Healthcare-associated Infectious Disease Diagnostics Market Research Report by Product & Service, by Disease Type, by End-user - Global Forecast to 2025 - Cumulative Impact of COVID-19

出版日: | 発行: 360iResearch LLP | ページ情報: 英文 187 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=109.37円
医療関連感染症診断の市場調査レポート:製品とサービス別、疾患タイプ別、エンドユーザー別(2025年までの世界予測-COVID-19の累積的影響)
出版日: 2021年02月04日
発行: 360iResearch LLP
ページ情報: 英文 187 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の医療関連感染症診断の市場規模は、2020年に32億726万米ドル/28億1219万ユーロであり、2025年末までに45億6772万米ドル/40億506万ユーロ規模になる見込みです。

COVID-19は、未曾有の世界的な公衆衛生上の緊急事態であり、あらゆる業界に影響を及ぼしてきました。この長期的影響は、予測期間中に業界の成長に影響を与えると予測されています。私たちが進めている調査では、根底にあるCOVID-19の問題と今後の道筋を確実に扱うために、調査範囲を広げています。当レポートは、消費者の行動と需要の変化、購入パターン、サプライチェーンの再ルーティング、現在の市場動向、および政府の重要な介入などを考慮しながら、COVID-19について洞察を提供しています。

当レポートでは、医療関連感染症診断市場を調査し、市場概要、市場の成長要因および阻害要因の分析、製品とサービス別、疾患タイプ別、エンドユーザー別の市場規模の推移と予測、COVID-19の累積的影響、競合情勢、主要企業のプロファイル、市場機会など、包括的な情報を提供しています。

目次

第1章 序文

  • 調査の目的
  • 市場セグメンテーションとカバレッジ
  • 調査対象年
  • 通貨と価格
  • 言語
  • 制限事項
  • 利害関係者

第2章 調査手法

  • 調査プロセス
    • 定義:調査目的
    • 決定:調査デザイン
    • 準備:調査機器
    • 収集:データソース
    • 分析:データの解釈
    • 策定:データ検証
    • 公開:調査レポート
    • 繰り返し:レポートの更新
  • 調査の実行
    • 開始:調査プロセス
    • 計画:調査計画作成
    • 実行:調査実施
    • 検証:発見と分析
    • 出版物:調査報告
  • 調査成果

第3章 エグゼクティブサマリー

  • イントロダクション
  • 市場の見通し
  • 製品とサービス別の見通し
  • エンドユーザー別の見通し
  • 疾患タイプ別の見通し
  • 地域別展望
  • 競合他社別の見通し

第4章 市場概要

  • イントロダクション
  • COVID-19の累積的影響
  • 地理的な成長機会

第5章 市場の洞察

  • 市場力学
    • 促進要因
    • 抑制要因
    • 市場機会
    • 課題
  • ポーターズファイブフォース分析
    • 新規参入業者の脅威
    • 代替品の脅威
    • 顧客の交渉力
    • 供給企業の交渉力
    • 業界の競争

第6章 世界の医療関連感染症診断市場:製品およびサービス別

  • イントロダクション
  • アッセイ、キット、および試薬
  • 精密器具
  • サービスとソフトウェア

第7章 世界の医療関連感染症診断市場:疾患タイプ別

  • イントロダクション
  • クラミジアトラコマチス生殖器感染症と淋病
  • 肝炎
  • 院内感染
  • ヒト免疫不全ウイルス
  • ヒトパピローマウイルス
  • インフルエンザ
  • 結核

第8章 世界の医療関連感染症診断市場:エンドユーザー別

  • イントロダクション
  • 学術/調査機関
  • 病院/臨床検査室
  • 医師のオフィス
  • リファレンスラボ

第9章 南北アメリカの医療関連感染症診断市場

  • イントロダクション
  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第10章 アジア太平洋地域の医療関連感染症診断市場

  • イントロダクション
  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • 韓国
  • タイ

第11章 欧州、中東・アフリカの医療関連感染症診断市場

  • イントロダクション
  • フランス
  • ドイツ
  • イタリア
  • オランダ
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • アラブ首長国連邦
  • 英国

第12章 競合情勢

  • FPNVポジショニングマトリックス
    • 象限
    • 事業戦略
    • 製品の満足度
  • 市場ランキング分析
  • 市場シェア分析
  • 競合シナリオ
    • 合併と買収
    • 合意、コラボレーション、およびパートナーシップ
    • 新製品の発売と強化
    • 投資と資金調達
    • 賞、表彰、拡大

第13章 企業のユーザビリティプロファイル

  • Abbott Laboratories
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Biomerieux SA
  • Co-Diagnostics Inc.
  • Danaher Corporation
  • DiaSorin S.p.A.
  • DNAe Group Holdings Ltd
  • GNA Biosolutions GmbH
  • Luminex Corporation
  • Meridian Bioscience Inc.
  • Quidel Corporation
  • Roche Holding AG
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.

第14章 付録

  • ディスカッションガイド
図表

List of Figures

  • FIGURE 1. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET: RESEARCH PROCESS
  • FIGURE 2. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET: RESEARCH EXECUTION
  • FIGURE 3. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, 2020 VS 2025 (USD MILLION)
  • FIGURE 4. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2020 (USD MILLION)
  • FIGURE 5. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2020 (USD MILLION)
  • FIGURE 6. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2020 (USD MILLION)
  • FIGURE 7. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2020 (USD MILLION)
  • FIGURE 8. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, 2018-2025 (USD MILLION)
  • FIGURE 9. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
  • FIGURE 10. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
  • FIGURE 11. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2025
  • FIGURE 12. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET: MARKET DYNAMICS
  • FIGURE 13. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET: PORTERS FIVE FORCES ANALYSIS
  • FIGURE 14. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2020 VS 2025 (%)
  • FIGURE 15. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2020 VS 2025 (USD MILLION)
  • FIGURE 16. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2025
  • FIGURE 17. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ASSAYS, KITS, & REAGENTS, 2020 VS 2025 (USD MILLION)
  • FIGURE 18. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2020 VS 2025 (USD MILLION)
  • FIGURE 19. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SERVICES & SOFTWARE, 2020 VS 2025 (USD MILLION)
  • FIGURE 20. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2020 VS 2025 (%)
  • FIGURE 21. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2020 VS 2025 (USD MILLION)
  • FIGURE 22. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2025
  • FIGURE 23. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CHLAMYDIA TRACHOMATIS GENITAL INFECTION AND GONORRHEA, 2020 VS 2025 (USD MILLION)
  • FIGURE 24. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY HEPATITIS, 2020 VS 2025 (USD MILLION)
  • FIGURE 25. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITAL-ACQUIRED INFECTIONS, 2020 VS 2025 (USD MILLION)
  • FIGURE 26. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY HUMAN IMMUNODEFICIENCY VIRUS, 2020 VS 2025 (USD MILLION)
  • FIGURE 27. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY HUMAN PAPILLOMAVIRUS, 2020 VS 2025 (USD MILLION)
  • FIGURE 28. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY INFLUENZA, 2020 VS 2025 (USD MILLION)
  • FIGURE 29. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY TUBERCULOSIS, 2020 VS 2025 (USD MILLION)
  • FIGURE 30. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2020 VS 2025 (%)
  • FIGURE 31. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2020 VS 2025 (USD MILLION)
  • FIGURE 32. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2025
  • FIGURE 33. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ACADEMIC/RESEARCH INSTITUTES, 2020 VS 2025 (USD MILLION)
  • FIGURE 34. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITAL/CLINICAL LABORATORIES, 2020 VS 2025 (USD MILLION)
  • FIGURE 35. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PHYSICIAN OFFICES, 2020 VS 2025 (USD MILLION)
  • FIGURE 36. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY REFERENCE LABORATORIES, 2020 VS 2025 (USD MILLION)
  • FIGURE 37. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
  • FIGURE 38. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
  • FIGURE 39. COMPETITIVE STRATEGIC WINDOW FOR AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2025
  • FIGURE 40. ARGENTINA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 41. BRAZIL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 42. CANADA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 43. MEXICO HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 44. UNITED STATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 45. ASIA-PACIFIC HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
  • FIGURE 46. ASIA-PACIFIC HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
  • FIGURE 47. COMPETITIVE STRATEGIC WINDOW FOR ASIA-PACIFIC HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2025
  • FIGURE 48. AUSTRALIA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 49. CHINA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 50. INDIA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 51. INDONESIA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 52. JAPAN HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 53. MALAYSIA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 54. PHILIPPINES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 55. SOUTH KOREA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 56. THAILAND HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 57. EUROPE, MIDDLE EAST & AFRICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
  • FIGURE 58. EUROPE, MIDDLE EAST & AFRICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
  • FIGURE 59. COMPETITIVE STRATEGIC WINDOW FOR EUROPE, MIDDLE EAST & AFRICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2025
  • FIGURE 60. FRANCE HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 61. GERMANY HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 62. ITALY HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 63. NETHERLANDS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 64. QATAR HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 65. RUSSIA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 66. SAUDI ARABIA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 67. SOUTH AFRICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 68. SPAIN HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 69. UNITED ARAB EMIRATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 70. UNITED KINGDOM HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 71. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET: 360IRESEARCH™ FPNV POSITIONING MATRIX
  • FIGURE 72. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET: 360IRESEARCH™ MARKET SHARE ANALYSIS
  • FIGURE 73. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET: COMPETITOR SWOT ANALYSIS
  • FIGURE 74. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE

List of Tables

  • TABLE 1. CURRENCY CONVERSION RATES
  • TABLE 2. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 3. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 4. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 5. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ASSAYS, KITS, & REAGENTS, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 6. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 7. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SERVICES & SOFTWARE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 8. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 9. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CHLAMYDIA TRACHOMATIS GENITAL INFECTION AND GONORRHEA, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 10. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY HEPATITIS, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 11. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITAL-ACQUIRED INFECTIONS, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 12. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY HUMAN IMMUNODEFICIENCY VIRUS, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 13. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY HUMAN PAPILLOMAVIRUS, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 14. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY INFLUENZA, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 15. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY TUBERCULOSIS, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 16. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 17. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ACADEMIC/RESEARCH INSTITUTES, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 18. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITAL/CLINICAL LABORATORIES, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 19. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PHYSICIAN OFFICES, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 20. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY REFERENCE LABORATORIES, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 21. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 22. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 23. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 24. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 25. ARGENTINA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 26. ARGENTINA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 27. ARGENTINA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 28. BRAZIL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 29. BRAZIL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 30. BRAZIL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 31. CANADA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 32. CANADA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 33. CANADA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 34. MEXICO HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 35. MEXICO HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 36. MEXICO HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 37. UNITED STATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 38. UNITED STATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 39. UNITED STATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 40. ASIA-PACIFIC HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 41. ASIA-PACIFIC HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 42. ASIA-PACIFIC HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 43. ASIA-PACIFIC HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 44. AUSTRALIA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 45. AUSTRALIA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 46. AUSTRALIA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 47. CHINA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 48. CHINA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 49. CHINA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 50. INDIA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 51. INDIA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 52. INDIA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 53. INDONESIA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 54. INDONESIA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 55. INDONESIA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 56. JAPAN HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 57. JAPAN HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 58. JAPAN HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 59. MALAYSIA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 60. MALAYSIA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 61. MALAYSIA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 62. PHILIPPINES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 63. PHILIPPINES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 64. PHILIPPINES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 65. SOUTH KOREA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 66. SOUTH KOREA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 67. SOUTH KOREA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 68. THAILAND HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 69. THAILAND HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 70. THAILAND HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 71. EUROPE, MIDDLE EAST & AFRICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 72. EUROPE, MIDDLE EAST & AFRICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 73. EUROPE, MIDDLE EAST & AFRICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 74. EUROPE, MIDDLE EAST & AFRICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 75. FRANCE HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 76. FRANCE HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 77. FRANCE HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 78. GERMANY HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 79. GERMANY HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 80. GERMANY HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 81. ITALY HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 82. ITALY HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 83. ITALY HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 84. NETHERLANDS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 85. NETHERLANDS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 86. NETHERLANDS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 87. QATAR HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 88. QATAR HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 89. QATAR HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 90. RUSSIA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 91. RUSSIA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 92. RUSSIA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 93. SAUDI ARABIA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 94. SAUDI ARABIA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 95. SAUDI ARABIA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 96. SOUTH AFRICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 97. SOUTH AFRICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 98. SOUTH AFRICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 99. SPAIN HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 100. SPAIN HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 101. SPAIN HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 102. UNITED ARAB EMIRATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 103. UNITED ARAB EMIRATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 104. UNITED ARAB EMIRATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 105. UNITED KINGDOM HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 106. UNITED KINGDOM HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 107. UNITED KINGDOM HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 108. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET: SCORES
  • TABLE 109. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET: BUSINESS STRATEGY
  • TABLE 110. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET: PRODUCT SATISFACTION
  • TABLE 111. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET: RANKING
  • TABLE 112. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET: MERGER & ACQUISITION
  • TABLE 113. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
  • TABLE 114. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
  • TABLE 115. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET: INVESTMENT & FUNDING
  • TABLE 116. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET: AWARD, RECOGNITION, & EXPANSION
  • TABLE 117. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET: LICENSE & PRICING
目次
Product Code: MRR-67AA438

Market Statistics:

The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. This helps organization leaders make better decisions when currency exchange data is readily available.

1. The Global Healthcare-associated Infectious Disease Diagnostics Market is expected to grow from USD 3,207.26 Million in 2020 to USD 4,567.72 Million by the end of 2025.

2. The Global Healthcare-associated Infectious Disease Diagnostics Market is expected to grow from EUR 2,812.19 Million in 2020 to EUR 4,005.06 Million by the end of 2025.

3. The Global Healthcare-associated Infectious Disease Diagnostics Market is expected to grow from GBP 2,500.04 Million in 2020 to GBP 3,560.51 Million by the end of 2025.

4. The Global Healthcare-associated Infectious Disease Diagnostics Market is expected to grow from JPY 342,296.84 Million in 2020 to JPY 487,491.94 Million by the end of 2025.

5. The Global Healthcare-associated Infectious Disease Diagnostics Market is expected to grow from AUD 4,657.38 Million in 2020 to AUD 6,632.94 Million by the end of 2025.

Market Segmentation & Coverage:

This research report categorizes the Healthcare-associated Infectious Disease Diagnostics to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Product & Service, the Healthcare-associated Infectious Disease Diagnostics Market studied across Assays, Kits, & Reagents, Instruments, and Services & Software.

Based on Disease Type, the Healthcare-associated Infectious Disease Diagnostics Market studied across Chlamydia Trachomatis Genital Infection and Gonorrhea, Hepatitis, Hospital-Acquired Infections, Human Immunodeficiency Virus, Human Papillomavirus, Influenza, and Tuberculosis.

Based on End-user, the Healthcare-associated Infectious Disease Diagnostics Market studied across Academic/Research Institutes, Hospital/Clinical Laboratories, Physician Offices, and Reference Laboratories.

Based on Geography, the Healthcare-associated Infectious Disease Diagnostics Market studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Company Usability Profiles:

The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Healthcare-associated Infectious Disease Diagnostics Market including Abbott Laboratories, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Biomerieux SA, Co-Diagnostics Inc., Danaher Corporation, DiaSorin S.p.A., DNAe Group Holdings Ltd, GNA Biosolutions GmbH, Luminex Corporation, Meridian Bioscience Inc., Quidel Corporation, Roche Holding AG, Siemens Healthineers AG, and Thermo Fisher Scientific Inc..

Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.

360iResearch™ FPNV Positioning Matrix:

The 360iResearch™ FPNV Positioning Matrix evaluates and categorizes the vendors in the Healthcare-associated Infectious Disease Diagnostics Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

360iResearch™ Competitive Strategic Window:

The 360iResearch™ Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The 360iResearch™ Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players

5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Healthcare-associated Infectious Disease Diagnostics Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Healthcare-associated Infectious Disease Diagnostics Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Healthcare-associated Infectious Disease Diagnostics Market?

4. What is the competitive strategic window for opportunities in the Global Healthcare-associated Infectious Disease Diagnostics Market?

5. What are the technology trends and regulatory frameworks in the Global Healthcare-associated Infectious Disease Diagnostics Market?

6. What are the modes and strategic moves considered suitable for entering the Global Healthcare-associated Infectious Disease Diagnostics Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Stakeholders

2. Research Methodology

  • 2.1. Research Process
    • 2.1.1. Define: Research Objective
    • 2.1.2. Determine: Research Design
    • 2.1.3. Prepare: Research Instrument
    • 2.1.4. Collect: Data Source
    • 2.1.5. Analyze: Data Interpretation
    • 2.1.6. Formulate: Data Verification
    • 2.1.7. Publish: Research Report
    • 2.1.8. Repeat: Report Update
  • 2.2. Research Execution
    • 2.2.1. Initiation: Research Process
    • 2.2.2. Planning: Develop Research Plan
    • 2.2.3. Execution: Conduct Research
    • 2.2.4. Verification: Finding & Analysis
    • 2.2.5. Publication: Research Report
  • 2.3. Research Outcome

3. Executive Summary

  • 3.1. Introduction
  • 3.2. Market Outlook
  • 3.3. Product & Service Outlook
  • 3.4. End-user Outlook
  • 3.5. Disease Type Outlook
  • 3.6. Geography Outlook
  • 3.7. Competitor Outlook

4. Market Overview

  • 4.1. Introduction
  • 4.2. Cumulative Impact of COVID-19

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Shift in focus from centralized laboratories to decentralized point-of-care testing
      • 5.1.1.2. Shift in focus from centralized laboratories to decentralized point-of-care testing
      • 5.1.1.3. Growth in funding for research on infectious disease diagnostics
    • 5.1.2. Restraints
      • 5.1.2.1. Stringent regulations to prevent HAIs in healthcare settings
      • 5.1.2.2. Sophisticated mechanisms available to control HAIs
    • 5.1.3. Opportunities
      • 5.1.3.1. Increase in target patients with healthcare-associated infections
      • 5.1.3.2. High growth potential in low and middle-income countries
      • 5.1.3.3. Growing penetration of POC tests to diagnose HAIs
    • 5.1.4. Challenges
      • 5.1.4.1. Inadequate reimbursements
      • 5.1.4.2. Low prevalence of HAIs in high-income nations
  • 5.2. Porters Five Forces Analysis
    • 5.2.1. Threat of New Entrants
    • 5.2.2. Threat of Substitutes
    • 5.2.3. Bargaining Power of Customers
    • 5.2.4. Bargaining Power of Suppliers
    • 5.2.5. Industry Rivalry

6. Global Healthcare-associated Infectious Disease Diagnostics Market, By Product & Service

  • 6.1. Introduction
  • 6.2. Assays, Kits, & Reagents
  • 6.3. Instruments
  • 6.4. Services & Software

7. Global Healthcare-associated Infectious Disease Diagnostics Market, By Disease Type

  • 7.1. Introduction
  • 7.2. Chlamydia Trachomatis Genital Infection and Gonorrhea
  • 7.3. Hepatitis
  • 7.4. Hospital-Acquired Infections
  • 7.5. Human Immunodeficiency Virus
  • 7.6. Human Papillomavirus
  • 7.7. Influenza
  • 7.8. Tuberculosis

8. Global Healthcare-associated Infectious Disease Diagnostics Market, By End-user

  • 8.1. Introduction
  • 8.2. Academic/Research Institutes
  • 8.3. Hospital/Clinical Laboratories
  • 8.4. Physician Offices
  • 8.5. Reference Laboratories

9. Americas Healthcare-associated Infectious Disease Diagnostics Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Healthcare-associated Infectious Disease Diagnostics Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. South Korea
  • 10.10. Thailand

11. Europe, Middle East & Africa Healthcare-associated Infectious Disease Diagnostics Market

  • 11.1. Introduction
  • 11.2. France
  • 11.3. Germany
  • 11.4. Italy
  • 11.5. Netherlands
  • 11.6. Qatar
  • 11.7. Russia
  • 11.8. Saudi Arabia
  • 11.9. South Africa
  • 11.10. Spain
  • 11.11. United Arab Emirates
  • 11.12. United Kingdom

12. Competitive Landscape

  • 12.1. FPNV Positioning Matrix
    • 12.1.1. Quadrants
    • 12.1.2. Business Strategy
    • 12.1.3. Product Satisfaction
  • 12.2. Market Ranking Analysis
  • 12.3. Market Share Analysis
  • 12.4. Competitor SWOT Analysis
  • 12.5. Competitive Scenario
    • 12.5.1. Merger & Acquisition
    • 12.5.2. Agreement, Collaboration, & Partnership
    • 12.5.3. New Product Launch & Enhancement
    • 12.5.4. Investment & Funding
    • 12.5.5. Award, Recognition, & Expansion

13. Company Usability Profiles

  • 13.1. Abbott Laboratories
  • 13.2. Becton, Dickinson and Company
  • 13.3. Bio-Rad Laboratories, Inc.
  • 13.4. Biomerieux SA
  • 13.5. Co-Diagnostics Inc.
  • 13.6. Danaher Corporation
  • 13.7. DiaSorin S.p.A.
  • 13.8. DNAe Group Holdings Ltd
  • 13.9. GNA Biosolutions GmbH
  • 13.10. Luminex Corporation
  • 13.11. Meridian Bioscience Inc.
  • 13.12. Quidel Corporation
  • 13.13. Roche Holding AG
  • 13.14. Siemens Healthineers AG
  • 13.15. Thermo Fisher Scientific Inc.

14. Appendix

  • 14.1. Discussion Guide
  • 14.2. License & Pricing
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.